Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $25,424 | $25,979 | $26,323 | $28,190 | $33,424 |
| Gross Profit | $4,737 | $19,525 | $19,917 | $19,739 | $20,566 |
| Operating Income | $9,139 | $7,639 | $9,566 | $7,897 | $7,258 |
| Net Income | $7,264 | $5,893 | $6,552 | $6,717 | $4,090 |
Over the five-year period, Amgen’s revenue has shown a steady upward trend, increasing from USD 25,424 million in 2020 to USD 33,424 million in 2024. This growth, roughly 31.5% over the period, indicates a healthy top-line performance despite the fluctuations in other key earnings metrics. Gross profit, however, presents a unique trend: after a marked jump from USD 4,737 million in 2020 to USD 19,525 million in 2021, it has remained relatively in the same range, with a slight increase to USD 20,566 million in 2024. This abrupt increase in 2021 might reflect a change in accounting practices or operational efficiencies that were introduced at that time. Operating income and net income trends offer further insights. Operating income fluctuated over the years—starting at USD 9,139 million, dipping to USD 7,639 million in 2021, rising to USD 9,566 million in 2022, and then declining to USD 7,258 million in 2024. Net income followed a somewhat similar pattern, with a notable decline from USD 7,264 million in 2020 to USD 5,893 million in 2021, modest recoveries thereafter, and a significant drop of nearly 39% from USD 6,717 million in 2023 to USD 4,090 million in 2024. This marked swing in net income suggests rising operational expenses or margin pressures which may be influenced by industry dynamics such as increased R&D investments or competitive pricing challenges in the biopharmaceutical sector. Overall, while revenue growth and a steadily high gross profit underscore Amgen’s robust market position, the declining operating and net income, particularly in 2024, raise concerns about sustainability and efficiency in translating revenue growth to bottom-line profitability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.